ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023
March 07 2023 - 4:05PM
Business Wire
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that
the company will report financial results for the three months and
year ended December 31, 2022 on Tuesday, March 14, 2023 after the
close of trading on the U.S. financial markets. Management will
host a conference call and webcast beginning at 4:30 p.m. Eastern
time to discuss the results, provide an update on recent corporate
developments and answer questions.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will receive a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the call start time. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call can also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until March 21, 2023 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 2113040. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 500,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230307005976/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Oct 2023 to Oct 2024